To provide for digital communication of prescribing information for drugs (including biological products), and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill requires digital communication of FDA-approved prescribing information for drugs (including biological products) Section 502(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. It relies on definition changes, compliance mandates, product standards, and delegation of rulemaking. The main policy areas are Healthcare Consumers, Finance, and Healthcare.
Who Benefits and How
Public beneficiaries or protected communities affected by the clause could face reduced risk.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Patients and health care consumers affected by the bill would take on compliance duties, and Businesses and employers affected by the bill would take on compliance duties.
Key Provisions
- Requires digital communication of FDA-approved prescribing information for drugs (including biological products) Section 502(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill requires digital communication of FDA-approved prescribing information for drugs (including biological products) Section 502(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
Key Policy Areas
Healthcare Consumers, Finance, Healthcare
Primary Purpose
The bill requires digital communication of FDA-approved prescribing information for drugs (including biological products) Section 502(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
Policy Domains
Whole bill
Identified Gains
- Public beneficiaries or protected communities affected by the clause
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Patients and health care consumers affected by the bill
- Businesses and employers affected by the bill
Sponsors
Legislative Progress
IntroducedMrs. Harshbarger (for herself and Ms. Sherrill) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology